



OXBRYTA® (voxelotor) WITHDRAWAL FREQUENTLY ASKED QUESTIONS AND RESOURCES

Dear Sickle Cell Warriors and Families,

Pfizer has announced that at this time, we are voluntarily withdrawing OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) in all markets where it is approved. We are saddened and disappointed by this decision. We want you to know that we did not make it lightly and your safety was our top consideration when making this decision. Patient safety has been and will always be our top priority.

Please contact your healthcare provider to discuss your care plan. Please also see below for answers to questions you may have.

Q: What should I do if OXBRYTA was helping me and I can no longer take it?

Pfizer cannot provide medical advice, and you should connect directly with your healthcare provider to discuss how best to proceed. If you have more questions about OXBRYTA, please talk to your healthcare provider or contact Pfizer Medical Information at 1-800-438-1985.

Q: Why was OXBRYTA withdrawn from the market?

Pfizer's decision is based on all of the available clinical data that now suggests the overall benefit of OXBRYTA no longer outweighs the risk of the approved sickle cell patient population.

Q: What exactly were the new findings that caused the withdrawal?

The data suggests an imbalance in vaso-occlusive crises (acute painful episodes) and fatalities (deaths), which we need to review further.

Q: What guidance has been provided for weaning off OXBRYTA?

Pfizer cannot provide medical advice. Please talk to your healthcare provider about your care plan; they should monitor you for adverse events after you stop taking OXBRYTA and follow up with you as appropriate.

Q: Is compassionate use of OXBRYTA still allowed for patients who benefitted from the drug?

No. Pfizer has withdrawn all lots of OXBRYTA and has discontinued all clinical trials and expanded access programs at this time.

Q: Will Pfizer consider returning OXBRYTA to the market, and if so, when?

We are further reviewing the available data and investigating the findings. We will continue to update you as fully and as quickly as we can. In the meantime, you may consider the resources listed below.

RESOURCES:

- **Connect with a Patient Affairs Liaison:** The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. To contact a PAL, visit

www.togetherforrare.com, click on “schedule a meeting with your PAL” in the center of the page and fill in the three prompts. Your local PAL will reach out to you shortly.

- Visit www.sicklecellspeaks.com for more information on sickle cell disease diagnosis, management, and support resources.
- **Return unused OXBRYTA pills for reimbursement:** To properly dispose of unused medication, please call a dedicated OXBRYTA line during normal business hours, Monday–Friday, 8:00 am–5:00 pm ET at 888-548-8521. **At no cost to you**, we will take your information and send you a return kit within 3–5 business days. You will then fill in the enclosed form, seal the package, adhere the label, and either drop off at a local UPS store or call UPS to pick it up. **You will be reimbursed for the amount you paid out-of-pocket for your OXBRYTA.**

Please see [Full Prescribing Information](#), including [Patient Information](#), for OXBRYTA.

If you have additional questions about OXBRYTA, please talk to your healthcare provider or contact Pfizer Medical Information at 1-800-438-1985.

The impact of this decision on you and your loved ones is not lost on us. Pfizer remains committed to our research to find much needed treatment options for people living with sickle cell disease. We will continue to update you as fully and as quickly as we can.